Cytokeratin 20 (CK20) and apomucin 1 (MUC1) expression in ampullary carcinoma: Correlation with tumor progression and prognosis
<p>Abstract</p> <p>Background</p> <p>We assessed the expression of cytokeratin (CK) and apomucin (MUC) in ampullary carcinoma (AC) to develop a system for the classification of ACs on the basis of their clinical significance.</p> <p>Method</p> <p>...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Book |
| Published: |
BMC,
2010-11-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_ca547db2b07c4eba9fc29a1d6aee5108 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Nishi Takeshi |e author |
| 700 | 1 | 0 | |a Inao Touko |e author |
| 700 | 1 | 0 | |a Nishisaka Takashi |e author |
| 700 | 1 | 0 | |a Tanaka Tsuneo |e author |
| 700 | 1 | 0 | |a Kawabata Yasunari |e author |
| 700 | 1 | 0 | |a Yano Seiji |e author |
| 245 | 0 | 0 | |a Cytokeratin 20 (CK20) and apomucin 1 (MUC1) expression in ampullary carcinoma: Correlation with tumor progression and prognosis |
| 260 | |b BMC, |c 2010-11-01T00:00:00Z. | ||
| 500 | |a 10.1186/1746-1596-5-75 | ||
| 500 | |a 1746-1596 | ||
| 520 | |a <p>Abstract</p> <p>Background</p> <p>We assessed the expression of cytokeratin (CK) and apomucin (MUC) in ampullary carcinoma (AC) to develop a system for the classification of ACs on the basis of their clinical significance.</p> <p>Method</p> <p>We studied the expressions of CK7, CK20, MUC1, MUC2, MUC5AC, and MUC6 in 43 patients with ACs. Clinical data were obtained retrospectively by examining surgically resected ACs of the patients.</p> <p>Results</p> <p>We classified the cases into 3 groups: tumors expressing CK20 and lacking MUC1 (intestinal type [I-type], 26%), tumors expressing MUC1 and lacking CK20 (pancreatobiliary type [PB-type], 35%), and those expressing or lacking both CK20 and MUC1 (other type [O-type], 39%). Eight (73%) of 11 I-type carcinomas, 3 (20%) of 15 PB-type carcinomas, and 4 (24%) of 17 O-type carcinomas were classified as pT1. The number of I-type carcinomas in the early tumor stages was significantly higher than the number of PB- and O-type carcinomas (p = 0.014 and p = 0.018, respectively). The 5-year survival rates for pT1, pT2, and pT3 tumors were 76%, 33%, and 22%, respectively (p < 0.001). Rates of MUC5AC and MUC6 coexpression for I-type, PB-type, and O-type tumors were 18%, 13%, and 53%, respectively. There was a significant correlation between MUC5AC and MUC6 coexpression and O-type characteristics (p = 0.031). The five-year survival rates for O-type ACs with and without MUC5AC and MUC6 coexpression were 71% and 17%, respectively (p = 0.048).</p> <p>Conclusions</p> <p>The immunohistochemical subtypes based on CK and MUC expression correlated with tumor progression. Gastric MUC5AC and MUC6 coexpression correlated with better prognosis for O-type ACs.</p> | ||
| 546 | |a EN | ||
| 690 | |a Pathology | ||
| 690 | |a RB1-214 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Diagnostic Pathology, Vol 5, Iss 1, p 75 (2010) | |
| 787 | 0 | |n http://www.diagnosticpathology.org/content/5/1/75 | |
| 787 | 0 | |n https://doaj.org/toc/1746-1596 | |
| 856 | 4 | 1 | |u https://doaj.org/article/ca547db2b07c4eba9fc29a1d6aee5108 |z Connect to this object online. |